Welcome to our dedicated page for GSK PLC news (Ticker: GSK), a resource for investors and traders seeking the latest updates and insights on GSK PLC stock.
News and regulatory disclosures for GSK plc (GSK) highlight the company’s ongoing activity across medicines, vaccines and strategic collaborations. As a global biopharma company, GSK regularly reports clinical trial milestones, product approvals, public health initiatives and agreements with partners and governments.
Recent news includes multiple regulatory approvals and data readouts in respiratory medicine. GSK has announced approvals for Exdensur (depemokimab) in markets such as Japan for severe asthma and chronic rhinosinusitis with nasal polyps, based on the SWIFT and ANCHOR phase III trials. The company has also reported that Nucala (mepolizumab) was approved in China as an add-on maintenance treatment for adults with COPD characterized by raised blood eosinophils, supported by the MATINEE and METREX studies.
In vaccines, GSK issues updates on Shingrix, including US FDA and European Commission approvals of a prefilled syringe presentation designed to simplify administration, and on its seasonal influenza vaccines FLULAVAL and FLUARIX, which are shipped ahead of each US flu season following FDA lot-release. News about Vaccine Track, GSK’s public data tool for US adult immunization trends, provides additional context on the company’s role in vaccination and public health analytics.
Oncology and specialty medicine updates feature prominently in GSK news. The company has reported US FDA approval of Blenrep in combination regimens for relapsed or refractory multiple myeloma, as well as positive phase III results for bepirovirsen in chronic hepatitis B with plans for global regulatory submissions. Additional releases describe collaborations with partners such as Hengrui Pharma and Summit Therapeutics to develop new respiratory, immunology & inflammation and oncology programs.
Investors and observers following GSK news can expect coverage of clinical trial outcomes, regulatory decisions, pricing and access agreements, and community initiatives such as the Linked by Lupus: Optimal Care Initiative. Bookmarking this page provides a centralized view of GSK’s latest announcements and SEC-reported developments.
Eligo Bioscience has signed a research and option agreement with GlaxoSmithKline (GSK) to advance its breakthrough treatment, EB005, targeting acne vulgaris through CRISPR-based technology. Eligo will receive an upfront payment and funding to progress EB005 until preclinical proof of concept. If GSK opts in, Eligo could earn up to $224 million in fees and milestone payments, plus royalties on sales. The partnership aims to address acne's root causes by selectively modulating the skin's microbiome, potentially changing treatment paradigms in the industry.
GSK has received FDA approval for BENLYSTA (belimumab) to treat adult patients with active lupus nephritis (LN) in conjunction with standard therapy. This marks a significant advancement as BENLYSTA is the first approved medication for this condition in over 50 years. The approval, based on the successful BLISS-LN study, showed 43% of patients treated with BENLYSTA achieved Primary Efficacy Renal Response compared to 32% with placebo. The treatment aims to improve renal outcomes and delay kidney replacement therapies, addressing a critical need in the lupus community.
Summary not available.
GSK Consumer Healthcare has launched Robitussin Naturals, its first drug-free line aimed at relieving occasional coughs. As the leading cough relief brand, Robitussin leverages over 70 years of experience to introduce these new dietary supplements formulated with natural ingredients like True Source certified honey and English ivy. The brand has partnered with cheer coach Monica Aldama to promote these products, emphasizing their appeal to health-conscious consumers. Robitussin Naturals products are now available in drugstores nationwide.
ViiV Healthcare announced the launch of a new weekly podcast titled Being Seen, which explores cultural representations relevant to the queer and gay Black male experience. Hosted by Darnell Moore, the podcast aims to change perceptions and reduce stigma surrounding this community, emphasizing their stories and challenges. Available starting October 6, Being Seen features conversations with various artists and activists. This initiative aligns with ViiV's focus on addressing HIV-related disparities and amplifying marginalized voices in society.
GSK Consumer Healthcare has launched Advil Dual Action, a groundbreaking over-the-counter pain relief formula that combines ibuprofen and acetaminophen, becoming the first FDA-approved of its kind in 25 years. This innovative product targets pain through two mechanisms: directly at the source and by blocking pain signals to the brain. Acclaimed actress Angela Kinsey is the face of the launch, aiming to showcase its efficacy in managing everyday aches and pains. A survey reveals 95% of adults experience pain, with 80% seeking better relief options, highlighting significant market potential for Advil Dual Action.
GSK Consumer Healthcare launched Advil Dual Action, an innovative over-the-counter pain relief solution combining ibuprofen and acetaminophen. This launch follows FDA approval, marking a significant milestone as the first product of its kind in the OTC market. A recent survey revealed that while 95% of Americans experience pain, 80% do not find complete relief with existing medications. Advil aims to enhance pain management discussions with a modern emoji scale for pain representation. Advil Dual Action is available online and in stores nationwide.
On July 14, 2020, GlaxoSmithKline (GSK) announced that the FDA Oncologic Drugs Advisory Committee voted 12-0 in favor of the benefit-risk profile of belantamab mafodotin, an investigational treatment for relapsed or refractory multiple myeloma. The committee recognized its potential for patients who have undergone at least four prior therapies. The recommendation stems from the DREAMM-2 clinical trial. While the FDA may consider this recommendation, it is not obliged to follow it. Belantamab mafodotin is not yet approved worldwide.